Literature DB >> 8764625

Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

J H Simon1.   

Abstract

Magnetic resonance-based measures of disease activity and progression are now routinely used in definitive phase III treatment trials of multiple sclerosis as important secondary outcome measures because they provide quantitative and objective confirmation of the primary clinical outcome measures. Magnetic resonance-based activity measures can also be used as an efficient mechanism for screening therapies in phase I and II trials. In this review I consider the natural history of multiple sclerosis lesions and the relationships between magnetic resonance measures and clinical observations of disease as the basis for the use of magnetic resonance markers in current and future treatment trials.

Entities:  

Mesh：

Year:  1996        PMID： 8764625      PMCID： PMC1303626     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


  63 in total

1.  Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

Authors:  F Barkhof; P Scheltens; S T Frequin; J J Nauta; M W Tas; J Valk; O R Hommes
Journal:  AJR Am J Roentgenol       Date:  1992-11       Impact factor: 3.959

2.  Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue.

Authors:  J Newcombe; C P Hawkins; C L Henderson; H A Patel; M N Woodroofe; G M Hayes; M L Cuzner; D MacManus; E P du Boulay; W I McDonald
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

3.  Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques.

Authors:  P A Narayana; J S Wolinsky; E F Jackson; M McCarthy
Journal:  J Magn Reson Imaging       Date:  1992 May-Jun       Impact factor: 4.813

4.  Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.

Authors:  A J Thompson; D Miller; B Youl; D MacManus; S Moore; D Kingsley; B Kendall; A Feinstein; W I McDonald
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

5.  Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

Authors:  J O Harris; J A Frank; N Patronas; D E McFarlin; H F McFarland
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

6.  Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis.

Authors:  D W Paty; D K Li; J J Oger; L Kastrukoff; R Koopmans; E Tanton; G J Zhao
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

7.  Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy.

Authors:  G M Nesbit; G S Forbes; B W Scheithauer; H Okazaki; M Rodriguez
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

Review 8.  Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.

Authors:  T L Richards
Journal:  AJR Am J Roentgenol       Date:  1991-11       Impact factor: 3.959

9.  Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis.

Authors:  H B Larsson; P Christiansen; M Jensen; J Frederiksen; A Heltberg; J Olesen; O Henriksen
Journal:  Magn Reson Med       Date:  1991-11       Impact factor: 4.668

10.  Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging.

Authors:  V Dousset; R I Grossman; K N Ramer; M D Schnall; L H Young; F Gonzalez-Scarano; E Lavi; J A Cohen
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105
View more
  1 in total

1.  Magnetic resonance imaging in clinical therapeutic trials of multiple sclerosis.

Authors:  L Jacobs
Journal:  West J Med       Date:  1996-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.